Literature DB >> 30862721

MYC Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells.

Ran Tao1, Najiba Murad1, Zhenhua Xu1, Peng Zhang2, Konstantin Okonechnikov3,4, Marcel Kool3,4, Samuel Rivero-Hinojosa1, Christopher Lazarski1, Pan Zheng2, Yang Liu2, Charles G Eberhart5, Brian R Rood1, Roger Packer1, Yanxin Pei6.   

Abstract

A subset of group 3 medulloblastoma frequently harbors amplification or overexpression of MYC lacking additional focal aberrations, yet it remains unclear whether MYC overexpression alone can induce tumorigenesis and which cells give rise to these tumors. Here, we showed that astrocyte progenitors in the early postnatal cerebellum were susceptible to transformation by MYC. The resulting tumors specifically resembled human group 3 medulloblastoma based on histology and gene-expression profiling. Gene-expression analysis of MYC-driven medulloblastoma cells revealed altered glucose metabolic pathways with marked overexpression of lactate dehydrogenase A (LDHA). LDHA abundance correlated positively with MYC expression and was associated with poor prognosis in human group 3 medulloblastoma. Inhibition of LDHA significantly reduced growth of both mouse and human MYC-driven tumors but had little effect on normal cerebellar cells or SHH-associated medulloblastoma. By generating a new mouse model, we demonstrated for the first time that astrocyte progenitors can be transformed by MYC and serve as the cells of origin for group 3 medulloblastoma. Moreover, we identified LDHA as a novel, specific therapeutic target for this devastating disease. SIGNIFICANCE: Insights from a new model identified LDHA as a novel target for group 3 medulloblastoma, paving the way for the development of effective therapies against this disease. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30862721      PMCID: PMC6467710          DOI: 10.1158/0008-5472.CAN-18-1787

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  50 in total

Review 1.  Action of Myc in vivo - proliferation and apoptosis.

Authors:  S Pelengaris; B Rudolph; T Littlewood
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

2.  Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts.

Authors:  D W Felsher; A Zetterberg; J Zhu; T Tlsty; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

3.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain.

Authors:  Linda Madisen; Theresa A Zwingman; Susan M Sunkin; Seung Wook Oh; Hatim A Zariwala; Hong Gu; Lydia L Ng; Richard D Palmiter; Michael J Hawrylycz; Allan R Jones; Ed S Lein; Hongkui Zeng
Journal:  Nat Neurosci       Date:  2009-12-20       Impact factor: 24.884

4.  N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma.

Authors:  Samuel R Browd; Anna M Kenney; Oren N Gottfried; Joon Won Yoon; David Walterhouse; Carolyn A Pedone; Daniel W Fults
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

5.  Distinct thresholds govern Myc's biological output in vivo.

Authors:  Daniel J Murphy; Melissa R Junttila; Laurent Pouyet; Anthony Karnezis; Ksenya Shchors; Duyen A Bui; Lamorna Brown-Swigart; Leisa Johnson; Gerard I Evan
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

Review 6.  Inactivation of MYC reverses tumorigenesis.

Authors:  Y Li; S C Casey; D W Felsher
Journal:  J Intern Med       Date:  2014-07       Impact factor: 8.989

7.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.

Authors:  Marcel Kool; Andrey Korshunov; Marc Remke; David T W Jones; Maria Schlanstein; Paul A Northcott; Yoon-Jae Cho; Jan Koster; Antoinette Schouten-van Meeteren; Dannis van Vuurden; Steven C Clifford; Torsten Pietsch; Andre O von Bueren; Stefan Rutkowski; Martin McCabe; V Peter Collins; Magnus L Bäcklund; Christine Haberler; Franck Bourdeaut; Olivier Delattre; Francois Doz; David W Ellison; Richard J Gilbertson; Scott L Pomeroy; Michael D Taylor; Peter Lichter; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2012-02-23       Impact factor: 17.088

8.  Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.

Authors:  Rebecca M Hill; Sanne Kuijper; Janet C Lindsey; Kevin Petrie; Ed C Schwalbe; Karen Barker; Jessica K R Boult; Daniel Williamson; Zai Ahmad; Albert Hallsworth; Sarra L Ryan; Evon Poon; Simon P Robinson; Ruth Ruddle; Florence I Raynaud; Louise Howell; Colin Kwok; Abhijit Joshi; Sarah Leigh Nicholson; Stephen Crosier; David W Ellison; Stephen B Wharton; Keith Robson; Antony Michalski; Darren Hargrave; Thomas S Jacques; Barry Pizer; Simon Bailey; Fredrik J Swartling; William A Weiss; Louis Chesler; Steven C Clifford
Journal:  Cancer Cell       Date:  2014-12-18       Impact factor: 31.743

9.  Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.

Authors:  D Kawauchi; R J Ogg; L Liu; D J H Shih; D Finkelstein; B L Murphy; J E Rehg; A Korshunov; C Calabrese; F Zindy; T Phoenix; Y Kawaguchi; J Gronych; R J Gilbertson; P Lichter; A Gajjar; M Kool; P A Northcott; S M Pfister; M F Roussel
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

10.  The whole-genome landscape of medulloblastoma subtypes.

Authors:  Paul A Northcott; Ivo Buchhalter; A Sorana Morrissy; Volker Hovestadt; Joachim Weischenfeldt; Tobias Ehrenberger; Susanne Gröbner; Maia Segura-Wang; Thomas Zichner; Vasilisa A Rudneva; Hans-Jörg Warnatz; Nikos Sidiropoulos; Aaron H Phillips; Steven Schumacher; Kortine Kleinheinz; Sebastian M Waszak; Serap Erkek; David T W Jones; Barbara C Worst; Marcel Kool; Marc Zapatka; Natalie Jäger; Lukas Chavez; Barbara Hutter; Matthias Bieg; Nagarajan Paramasivam; Michael Heinold; Zuguang Gu; Naveed Ishaque; Christina Jäger-Schmidt; Charles D Imbusch; Alke Jugold; Daniel Hübschmann; Thomas Risch; Vyacheslav Amstislavskiy; Francisco German Rodriguez Gonzalez; Ursula D Weber; Stephan Wolf; Giles W Robinson; Xin Zhou; Gang Wu; David Finkelstein; Yanling Liu; Florence M G Cavalli; Betty Luu; Vijay Ramaswamy; Xiaochong Wu; Jan Koster; Marina Ryzhova; Yoon-Jae Cho; Scott L Pomeroy; Christel Herold-Mende; Martin Schuhmann; Martin Ebinger; Linda M Liau; Jaume Mora; Roger E McLendon; Nada Jabado; Toshihiro Kumabe; Eric Chuah; Yussanne Ma; Richard A Moore; Andrew J Mungall; Karen L Mungall; Nina Thiessen; Kane Tse; Tina Wong; Steven J M Jones; Olaf Witt; Till Milde; Andreas Von Deimling; David Capper; Andrey Korshunov; Marie-Laure Yaspo; Richard Kriwacki; Amar Gajjar; Jinghui Zhang; Rameen Beroukhim; Ernest Fraenkel; Jan O Korbel; Benedikt Brors; Matthias Schlesner; Roland Eils; Marco A Marra; Stefan M Pfister; Michael D Taylor; Peter Lichter
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

View more
  13 in total

1.  Astrocytes: new stars in the medulloblastoma firmament.

Authors:  Charles Eberhart
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

2.  OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.

Authors:  Zhenhua Xu; Najiba Murad; Daniel Malawsky; Ran Tao; Samuel Rivero-Hinojosa; Dörthe Holdhof; Ulrich Schüller; Peng Zhang; Christopher Lazarski; Brian R Rood; Roger Packer; Timothy Gershon; Yanxin Pei
Journal:  Clin Cancer Res       Date:  2022-10-03       Impact factor: 13.801

3.  Unified rhombic lip origins of group 3 and group 4 medulloblastoma.

Authors:  Kyle S Smith; Laure Bihannic; Brian L Gudenas; Parthiv Haldipur; Ran Tao; Qingsong Gao; Yiran Li; Kimberly A Aldinger; Igor Y Iskusnykh; Victor V Chizhikov; Matthew Scoggins; Silu Zhang; Angela Edwards; Mei Deng; Ian A Glass; Lynne M Overman; Jake Millman; Alexandria H Sjoboen; Jennifer Hadley; Joseph Golser; Kshitij Mankad; Heather Sheppard; Arzu Onar-Thomas; Amar Gajjar; Giles W Robinson; Volker Hovestadt; Brent A Orr; Zoltán Patay; Kathleen J Millen; Paul A Northcott
Journal:  Nature       Date:  2022-09-21       Impact factor: 69.504

4.  The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors.

Authors:  Jasmin Bartl; Marco Zanini; Flavia Bernardi; Antoine Forget; Lena Blümel; Julie Talbot; Daniel Picard; Nan Qin; Gabriele Cancila; Qingsong Gao; Soumav Nath; Idriss Mahoungou Koumba; Marietta Wolter; François Kuonen; Maike Langini; Thomas Beez; Christopher Munoz; David Pauck; Viktoria Marquardt; Hua Yu; Judith Souphron; Mascha Korsch; Christina Mölders; Daniel Berger; Sarah Göbbels; Frauke-Dorothee Meyer; Björn Scheffler; Barak Rotblat; Sven Diederichs; Vijay Ramaswamy; Hiromishi Suzuki; Anthony Oro; Kai Stühler; Anja Stefanski; Ute Fischer; Gabriel Leprivier; Dieter Willbold; Gerhard Steger; Alexander Buell; Marcel Kool; Peter Lichter; Stefan M Pfister; Paul A Northcott; Michael D Taylor; Arndt Borkhardt; Guido Reifenberger; Olivier Ayrault; Marc Remke
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

5.  Noncanonical activation of GLI signaling in SOX2+ cells drives medulloblastoma relapse.

Authors:  Marzena Swiderska-Syn; Júlia Mir-Pedrol; Alexander Oles; Olga Schleuger; April D Salvador; Sean M Greiner; Cara Seward; Fan Yang; Benjamin R Babcock; Chen Shen; Daniel T Wynn; Avencia Sanchez-Mejias; Timothy R Gershon; Vanesa Martin; Heather J McCrea; Kathryn G Lindsey; Carsten Krieg; Jezabel Rodriguez-Blanco
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

6.  Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.

Authors:  Nan Qin; Eunice Paisana; Maike Langini; Daniel Picard; Bastian Malzkorn; Carlos Custódia; Rita Cascão; Frauke-Dorothee Meyer; Lena Blümel; Sarah Göbbels; Kübra Taban; Jasmin Bartl; Nicole Bechmann; Catleen Conrad; Jan Gravemeyer; Jürgen C Becker; Anja Stefanski; Stéphanie Puget; João T Barata; Kai Stühler; Ute Fischer; Jörg Felsberg; Olivier Ayrault; Guido Reifenberger; Arndt Borkhardt; Graeme Eisenhofer; Claudia C Faria; Marc Remke
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

7.  An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.

Authors:  Thomas K Albert; Marta Interlandi; Martin Sill; Monika Graf; Natalia Moreno; Kerstin Menck; Astrid Rohlmann; Viktoria Melcher; Sonja Korbanka; Gerd Meyer Zu Hörste; Tobias Lautwein; Michael C Frühwald; Christian F Krebs; Dörthe Holdhof; Melanie Schoof; Annalen Bleckmann; Markus Missler; Martin Dugas; Ulrich Schüller; Natalie Jäger; Stefan M Pfister; Kornelius Kerl
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

8.  FAM46B Promotes Apoptosis and Inhibits Glycolysis of Prostate Cancer Through Inhibition of the MYC-LDHA Axis.

Authors:  Tao Liang; Xuxiao Ye; Dongliang Yan; Chao Deng; Zuowei Li; Binqiang Tian
Journal:  Onco Targets Ther       Date:  2020-09-01       Impact factor: 4.147

9.  Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells.

Authors:  Yingchao Xue; Yi Fu; Fenghong Zhao; Gege Gui; Yuguo Li; Samuel Rivero-Hinojosa; Guanshu Liu; Yunqing Li; Shuli Xia; Charles G Eberhart; Mingyao Ying
Journal:  Mol Cancer Ther       Date:  2021-03-15       Impact factor: 6.261

Review 10.  Drug Repurposing in Medulloblastoma: Challenges and Recommendations.

Authors:  Hussein Hammoud; Zahraa Saker; Hayat Harati; Youssef Fares; Hisham F Bahmad; Sanaa Nabha
Journal:  Curr Treat Options Oncol       Date:  2020-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.